Horizon Investments’s Neurocrine Biosciences NBIX Stock Holding History

Horizon Investments’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.65M	Sell	27,735 -27,355	-50%	-$3.63M	0.04%	345
2025 Q4	$7.81M	Buy	55,090 +16,474	+43%	+$2.39M	0.1%	173
2025 Q3	$5.42M	Buy	38,616 +28,903	+298%	+$3.92M	0.07%	224
2025 Q2	$1.22M	Buy	+9,713	New	+$1.11M	0.02%	520
2024 Q4	–	Sell	-16	Closed	-$1.84K	–	909
2024 Q3	$1.84K	Buy	16 +6	+60%	+$823	﹤0.01%	713
2024 Q2	$1.38K	Hold	10	–	–	﹤0.01%	722
2024 Q1	$1.38K	Buy	10 +6	+150%	+$819	﹤0.01%	705
2023 Q4	$527	Buy	+4	New	+$460	﹤0.01%	728

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Horizon Investments's NBIX Position: Q1 2026 in Review

Horizon Investments reduced its Neurocrine Biosciences (NBIX) stake by 50% in Q1 2026, selling an estimated $3.63M and leaving 27,735 shares worth $3.65M. The position accounts for 0.04% of the portfolio, ranked #345.

Horizon Investments first reported a position in NBIX in Q4 2023 and has held it in 8 quarters since. The position peaked at $7.81M in Q4 2025. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Horizon Investments held 27,735 shares of Neurocrine Biosciences worth $3.65M as of Q1 2026.
Horizon Investments sold 27,355 Neurocrine Biosciences shares in Q1 2026, an estimated $3.63M.
Neurocrine Biosciences made up 0.04% of Horizon Investments's portfolio in Q1 2026, its #345 holding.
Horizon Investments first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 8 quarters since.
Horizon Investments's Neurocrine Biosciences position peaked at $7.81M in Q4 2025.
696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Horizon Investments's 13F filing for Q1 2026, filed 15 May 2026.